Page 11 - CIRN Annual Report 2017
P. 11
CIRN NETWORKS AND THEIR PROJECTS
CIRN • 2017 ANNUAL REPORT 9
enrollment will begin in spring 2017.
CTN also embarked on its first African-Canadian collaboration with a phase II Ebola vaccine in HIV-affected populations study (ACHIV-Ebola). This international collaboration between the International Development Research Centre (IDRC), CIRN and Merck, with sites in Africa (Senegal, Burkina Faso) and Canada (Montreal, Ottawa), will evaluate the safety and tolerability of the VSV-Ebola vaccine in HIV-inf
eld work)
on salivary IgG and IgA ELISAs, with data analysis to begin in
September 2017. The Ebola-NML study is a 3-year NIH-led CIHR/PHAC-funded study in Winnipeg of pre-exposure prophylaxis (PREP) in people at increased risk of occupational (laboratory, clinical or fi exposure to Ebola virus. Participants receive a dose of VSV-Ebola and are randomized to a booster or no booster at 18 months. The study has Health Canada approval and will start screening in Spring 201